CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions.

TESTING SERVICES

Launched first commercial product, AlloMap^{^®} Heart, in 2005, now used by over 90% of U.S. transplant centers
Launched second surveillance product, AlloSure^{^®}, in 2017, using dd-cfDNA to determine graft injury
Ushering in the next generation in transplant management by leading the shift to multi-modality testing with HeartCare^{^®}, KidneyCare^TM, HistoMap, and UroMap

TRANSPLANT LAB PRODUCTS

Through a series of acquisitions in the 2010s, built portfolio of HLA typing solutions for matching donor organs with recipients

CareDX CEO on AI`s Role in Helping Improve Organ Transplant Care - Video